InMed Pharmaceuticals

Developing small molecule compounds for the treatment of #Alzheimers, Age-related #Macular Degeneration #AMD, & #EB. Our subsidiary @BayMedica NASDAQ: $INM

[InMed Pharmaceuticals @inmedpharma]

InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies

"This transaction provides us with the capital and public market infrastructure to aggressively compete in what we believe will be the next era of migraine prevention. Recent anti-PACAP clinical studies have validated this novel mechanism and generated tremendous excitement among headache specialists. MT-001 and MT-002 were designed to be potentially best-in-class, with superior convenience through subcutaneous delivery and the potential for enhanced efficacy through rational dual pathway inhibition. We have a clear regulatory path, rapid development timelines benchmarked to approved migraine therapies, and are focused on bringing these potentially transformative therapies to the millions of people who continue to suffer despite current treatment options."

~ Julie Bruno, Chair of Mentari’s Board of Directors

Read news release: https://t.co/uCJHvKP1l7

[InMed Pharmaceuticals @inmedpharma]

InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies

-Mentari’s parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies
-Concurrent oversubscribed US$290 million private placement of Mentari expected to fund company operations through 2028
-First-in-human regulatory filings for MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) expected mid-2026 and 1Q 2027, respectively

Read news release: https://t.co/uCJHvKP1l7

$INM

[InMed Pharmaceuticals @inmedpharma]

InMed Pharmaceuticals & Mentari Therapeutics Announce Merger

"This merger with Mentari represents an excellent opportunity for InMed shareholders to participate in the development of an exciting new drug pipeline with significant therapeutic and commercial potential. InMed’s Board of Directors and management team are in full support of this transaction and believe that Mentari’s strong balance sheet positions the company to successfully execute on the development plans for its parallel lead programs in the treatment of migraines. We believe Mentari's lead programs have tremendous potential to expand and reshape the migraine treatment and prevention market.”

~ Eric A. Adams, President & CEO of InMed

Read full news release: https://t.co/uCJHvKP1l7

$INM

[InMed Pharmaceuticals @inmedpharma]

Today, InMed announced a definitive merger agreement with Mentari Therapeutics to advance a pipeline of potentially best-in-class therapies for migraine prevention. The transaction includes a concurrent oversubscribed private investment of US$290 million led by Fairmount with participation from Commodore Capital, Deep Track Capital, Janus Henderson Investors, a16z Bio + Health, Venrock Healthcare Capital Partners, Wellington Management, TCGX, Blackstone Multi-Asset Investing, BB Biotech, Farallon Capital, RTW Investments, LP, Vivo Capital, Perceptive Advisors and other leading investment management firms.

The combined company will focus on advancing MT-001, an anti-PACAP monoclonal antibody, and MT-002, an anti-CGRP x PACAP bispecific antibody, which are expected to drive the next wave of migraine prevention, given that 40-50% of those taking currently approved therapies do not achieve a 50% reduction in monthly migraine days, and fewer than one-third have a 75% reduction.

The merger and associated financing are expected to fund the company's efforts through 2028, positioning us to rapidly advance the co-lead programs through key clinical data inflection points, with regulatory submissions expected mid-2026 (MT-001) and 1Q 2027 (MT-002).

We are thrilled to celebrate this transformative milestone with all involved.

Read more: https://t.co/uCJHvKP1l7

[InMed Pharmaceuticals @inmedpharma]

InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer’s Disease Program. See full press release: https://t.co/WKsmQ9OWs9

[InMed Pharmaceuticals @inmedpharma]

InMed's President and CEO, Eric A. Adams, presents at Renmark Financial's Virtual Non-Deal Roadshow on February 26, 2026.

In the presentation and Q&A, Mr. Adams gives an overview of the company's pharmaceutical programs, including lead drug candidate INM-901 for Alzheimer's disease, and answers these questions:

-How soon do you expect to start INM-901 Phase 1 clinical trial enrollment following a successful IND application?
-Will a Phase 1 clinical trial of INM-901 be conducted in healthy volunteers or in patients living with Alzheimer's disease?
-As INM-901 moves into the clinical development phase, do you expect to increase headcount or will this be outsourced?
-While you've had promising preclinical data of INM-901 so far, what gives you the confidence INM-901's preclinical results will translate similarly into human clinical trials?

Watch the presentation and Q&A here: https://t.co/ANjkfi0k9r

$INM #Alzheimers #pharma #neuroinflammation @RenmarkMedia

[InMed Pharmaceuticals @inmedpharma]

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

“Looking ahead in 2026, our primary focus is executing activities toward a pre-IND meeting with the FDA in Q3 to discuss the INM-901 program, which we believe will be a key inflection point as we work toward IND submission and initiation of a Phase 1 clinical trial in 2027." ~Eric A. Adams, CEO

Read news release: https://t.co/06i5pZt1Q7

$INM #alzheimers #pharma

[InMed Pharmaceuticals @inmedpharma]

#News: InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

"We further refined the program’s direction and reinforced our conviction that targeting neuroinflammation is critical to addressing Alzheimer’s disease progression.”

Read news release: https://t.co/2e9jHTUu5A

$INM #AlzheimersDisease #Alzheimers #neuroinflammation #pharma

[InMed Pharmaceuticals @inmedpharma]

#NEWS: InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

-Advancing Alzheimer’s and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling Activities
-Targeting Initiation of Phase 1 Clinical Trial in Alzheimer’s Disease in 2027

Read news release: https://t.co/jKawj4RaoQ

$INM #Alzheimers #DryAMD #AlzheimersDisease #pharma

[InMed Pharmaceuticals @inmedpharma]

InMed's CEO, Eric A. Adams, presents at the @RenmarkMedia Non-Deal Roadshow.

Eric presents the preclinical studies that demonstrate how INM-901 reduces neuroinflammation associated with Alzheimer's disease. He also talks about the role of CB1 and CB2 receptors in neuroinflammation.

Watch here: https://t.co/fuDHBdsC60

$INM #Alzheimers #AlzheimersDisease #research #neuroinflammation #inflammation

[InMed Pharmaceuticals @inmedpharma]

-How is InMed's INM-901 different from other Alzheimer’s therapeutics?

In this presentation, Mr. Adams speaks about how INM-901 targets the reduction of neuroinflammation. Neuroinflammation is now recognized as a key driver of Alzheimer’s disease development and progression. Mr. Adams also speaks about the upcoming development plans for INM-901 including its preparation for a pre-IND meeting with the FDA.

Watch video here: https://t.co/TRyfII6UUA

$INM #Alzheimers #neuroinflammation #preclinical #AlzheimersResearch #Pharma #Biotech #AlzheimersStudy

[InMed Pharmaceuticals @inmedpharma]

InMed today reports financial results for its second quarter of fiscal year 2026, which ended December 31, 2025.

During the quarter, InMed announced the successful completion of pharmacokinetic studies in clinically relevant in vivo models for INM-901. This marked the first preclinical study in which the oral formulation of INM-901 was administered in large animals. The results provide additional data in guiding decisions in the design of a human Phase 1 clinical trial program.

Full news release: https://t.co/OWadgO3UWM

$INM #Alzheimers #study #pharma #neuroinflammation

[InMed Pharmaceuticals @inmedpharma]

#NEWS InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

“We are pleased with the steady progress across our pharmaceutical pipeline as we look ahead to pursuing pre-IND meetings with the FDA in 2026. In our INM-901 program, compelling data from the preclinical studies demonstrated a significant reduction in key neuroinflammatory markers, reinforcing neuroinflammation as the central focus of our drug development activities.” ~ Eric A. Adams, CEO

Read full news release here: https://t.co/7mvC33tikB

$INM #Alzheimers #pipeline #pharma

[InMed Pharmaceuticals @inmedpharma]

#News: InMed Announces Results of 2025 Annual General and Special Meeting

Read news release here: https://t.co/btTnb9aKv4

$INM

[InMed Pharmaceuticals @inmedpharma]

InMed presents at the Life Sciences Virtual Investor Forum. CEO Eric A. Adams gives a company update and shares the preclinical data on InMed's lead compound INM-901 for #Alzheimers disease.

Presentation available on demand here: https://t.co/34KxTGlo07

$INM #lifesciences #pharma

[InMed Pharmaceuticals @inmedpharma]

What is the role of neuroinflammation in Alzheimer's disease development and progression?

This panel of #Alzheimers disease experts talk about what to expect in Alzheimer's research in the next few years and why #neuroinflammation is an important target for novel Alzheimer's treatments.

Discussion here: https://t.co/SQgdCiepNE

$INM #research #biotech #pharma #inflammation #AlzheimersDisease

[InMed Pharmaceuticals @inmedpharma]

Summary of InMed's INM-901 Pharmacokinetics Study:

-Over a seven-day dosing period, study demonstrated robust bioavailability with INM-901 achieving what is anticipated to be therapeutic levels of systemic exposure
-Neurological assessments evaluating general attitude, behavior, and motor function revealed no adverse neural or behavioral effects
-InMed has completed additional CMC development to scale manufacturing in preparation for pre-IND meeting with FDA

More here: https://t.co/znPLxqbf43

$INM #Alzheimers #PKStudies

[InMed Pharmaceuticals @inmedpharma]

Video Replay on Demand: InMed Presents at the Life Sciences Investor Forum.

InMed's CEO Eric A. Adams gives a progress update on InMed’s pipeline including recent data from the Company’s leading pharmaceutical program INM-901 in the treatment of Alzheimer’s disease. The new preclinical data was recently presented at the Alzheimer’s Association International Conference (AAIC) 2025, the world’s leading forum for Alzheimer’s disease and dementia research.

https://t.co/dhzsZ0uUgx

$INM #Alzheimers #pipeline #INM901 #preclinical #pharma

[InMed Pharmaceuticals @inmedpharma]

What is neuritogenesis?

In this video, InMed’s CEO, Eric A. Adams, explains the neuritogenesis process and how this process is essential for neuronal signaling and healthy brain functioning.

Video here: https://t.co/56fky59uat

$INM #neuritogenesis #Alzheimers #amyloidbeta #neurites

[InMed Pharmaceuticals @inmedpharma]

InMed has conducted several in vitro and in vivo studies to test the pharmacological effects of INM-901 in Alzheimer’s disease preclinical models with promising results demonstrating disease-modifying effects.

A summary of INM-901 preclinical study results:

➡️ Demonstrates neuroprotective effects by reducing cell death in an amyloid-beta-induced cytotoxicity study
➡️ Demonstrates significant reduction in inflammatory biomarkers associated with Alzheimer’s, including IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2 & NfL
➡️ May have a direct impact on neuroinflammation independent of the influence of amyloid beta or tau aggregation
➡️ Demonstrates an ability to promote neurite outgrowth, signifying the potential to improve neuronal function, a potential breakthrough in the treatment of Alzheimer’s disease
➡️ Demonstrates a trend in improvement in cognitive function and memory, locomotor activity, anxiety-based behavior, sound awareness and neuronal function
➡️ Demonstrates robust bioavailability in in vivo models, achieving what is anticipated to be therapeutic levels of systemic exposure
➡️ Additional mRNA data supports the observations made in behavior studies in locomotor activity, cognition and memory.

More about InMed's INM-901 program here: https://t.co/zkJgGcxfS9

$INM #Alzheimers #research #neuroprotection #neuroinflammation #pharma #biotech #studies